Overview
IPHA market data
Price History
No market bars yet for IPHA. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IPHA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data ReadoutBenzinga · Jul 21, 2026, 5:28 AM
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyBenzinga · Jun 2, 2026, 2:15 PM
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsightGlobenewswire Inc · May 21, 2026, 5:15 PM
Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026Benzinga · May 13, 2026, 5:31 AM